Pharmaceutical Research

, Volume 33, Issue 3, pp 739–750 | Cite as

Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations

Research Paper

Abstract

Purpose

The aims of this study were twofold. First, to evaluate the effectiveness of selected polymers in inhibiting solution crystallization of celecoxib. Second, to compare the release rate and crystallization tendency of celecoxib amorphous solid dispersions (ASDs) formulated with a single polymer, or binary polymer combinations.

Methods

The effectiveness of polymers, polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC) or HPMC acetate succinate (HPMCAS), in maintaining supersaturation of celecoxib solutions was evaluated by performing nucleation induction time measurements. Crystallization kinetics of ASD suspensions were monitored using Raman spectroscopy. Dissolution experiments were carried out under non-sink conditions.

Results

Pure amorphous celecoxib crystallized rapidly through both matrix and solution pathways. Matrix and solution crystallization was inhibited when celecoxib was molecularly mixed with a polymer, resulting in release of the drug to form supersaturated solutions. Cellulosic polymers were more effective than PVP in maintaining supersaturation. Combining a cellulosic polymer and PVP enabled improved drug release and stability to crystallization.

Conclusions

Inclusion of an effective solution crystallization inhibitor as a minor component in ternary dispersions resulted in prolonged supersaturation following dissolution. This study shows the feasibility of formulation strategies for ASDs where a major polymer component is used to achieve one key property e.g. release, while a minor polymer component is added to prevent crystallization.

KEY WORDS

amorphous solid dispersion crystallization dissolution supersaturation 

Abbreviations

ASD

Amorphous solid dispersion

CEX

Celecoxib

HPLC

High performance liquid chromatography

HPMC

Hydroxypropylmethyl cellulose

HPMCAS

Hydroxypropylmethyl cellulose acetate succinate

PVP

Polyvinyl pyrrolidone

SPB

Sodium phosphate buffer

UV

Ultraviolet

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

The Dane O. Kildsig Center for Pharmaceutical Processing Research is acknowledged for providing funding for this project.

References

  1. 1.
    Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4(4):403–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397–404.CrossRefPubMedGoogle Scholar
  3. 3.
    Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99(9):3787–806.Google Scholar
  4. 4.
    Trasi NS, Taylor LS. Effect of additives on crystal growth and nucleation of amorphous flutamide. Cryst Growth Des. 2012;12(6):3221–30.CrossRefGoogle Scholar
  5. 5.
    Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci. 2001;12(3):261–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kestur US, Taylor LS. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. Crystengcomm. 2010;12(8):2390–7.CrossRefGoogle Scholar
  7. 7.
    Kestur US, Van Eerdenbrugh B, Taylor LS. Influence of polymer chemistry on crystal growth inhibition of two chemically diverse organic molecules. Crystengcomm. 2011;13(22):6712–8.CrossRefGoogle Scholar
  8. 8.
    Alonzo DE, Zhang GGZ, Zhou DL, Gao Y, Taylor LS. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27(4):608–18.Google Scholar
  9. 9.
    Sohnel O, Mullin JW. Interpretation of crystallization induction periods. J Colloid Interf Sci. 1988;123(1):43–50.CrossRefGoogle Scholar
  10. 10.
    Ilevbare GA, Liu HY, Edgar KJ, Taylor LS. Maintaining supersaturation in aqueous drug solutions: impact of different polymers on induction times. Cryst Growth Des. 2013;13(2):740–51.CrossRefGoogle Scholar
  11. 11.
    Abu-Diak OA, Jones DS, Andrews GP. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol Pharmaceut. 2011;8(4):1362–71.CrossRefGoogle Scholar
  12. 12.
    Chen J, Ormes JD, Higgins JD, Taylor LS. Impact of surfactants on the crystallization of aqueous suspensions of celecoxib amorphous solid dispersion spray dried particles. Mol Pharmaceut. 2015;12(2):533–41.CrossRefGoogle Scholar
  13. 13.
    Trasi NS, Taylor LS. Effect of polymers on nucleation and crystal growth of amorphous acetaminophen. Crystengcomm. 2012;14(16):5188–97.CrossRefGoogle Scholar
  14. 14.
    Trasi NS, Oucherif KA, Litster JD, Taylor LS. Evaluating the influence of polymers on nucleation and growth in supersaturated solutions of acetaminophen. Crystengcomm. 2015;17(6):1242–8.CrossRefGoogle Scholar
  15. 15.
    Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70(2):493–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci-Us. 2006;95(12):2692–705.CrossRefGoogle Scholar
  17. 17.
    Rumondor ACF, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res. 2009;26(12):2599–606.Google Scholar
  18. 18.
    Marks JA, Wegiel LA, Taylor LS, Edgar KJ. Pairwise polymer blends for oral drug delivery. J Pharm Sci. 2014;103(9):2871–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Goddeeris C, Willems T, Van den Mooter G. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781. Eur J Pharm Sci. 2008;34(4–5):293–302.CrossRefPubMedGoogle Scholar
  20. 20.
    Janssens S, De Armas HN, Roberts CJ, Van Den Mooter G. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J Pharm Sci. 2008;97(6):2110–20.Google Scholar
  21. 21.
    Al-Obaidi H, Ke P, Brocchini S, Buckton G. Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int J Pharm. 2011;419(1–2):20–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Raina SA, Alonzo DE, Zhang GGZ, Gao Y, Taylor LS. Impact of polymers on the crystallization and phase transition kinetics of amorphous nifedipine during dissolution in aqueous media. Mol Pharmaceut. 2014;11(10):3565–76.CrossRefGoogle Scholar
  23. 23.
    Mullin JW. Crystallization: Butterworth-Heinemann; 2001.Google Scholar
  24. 24.
    Myerson A. Handbook of industrial crystallization: Butterworth-Heinemann; 2002.Google Scholar
  25. 25.
    Anwar J, Boateng PK, Tamaki R, Odedra S. Mode of action and design rules for additives that modulate crystal nucleation. Angew Chem Int Ed. 2009;48(9):1596–600.CrossRefGoogle Scholar
  26. 26.
    Warren DB, Benameur H, Porter CJH, Pouton CW. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Target. 2010;18(10):704–31.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Industrial and Physical Pharmacy, College of PharmacyPurdue UniversityWest LafayetteUSA

Personalised recommendations